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Abstract
Purpose: To evaluate the agreement between measured and calculated doses for head and neck tumors using different gamma
criteria and to establish quality assurance protocol for the delivery of IMRT in The National Cancer Institute in Cairo. Methods:
The dose is calculated for 30 patients using CMS Treatment Planning System. The ionization chamber (0.6 cm3 Farmer type) is
used for point dose measurements. The 2D-array (PTW 729) and GafChromic films (EBT2) are used for 2D graphical dose dis-
tribution. Four different gamma criteria of dose difference (DD) and distance to agreement (DTA) (3%/3 mm, 3%/5 mm, 4%/4
mm and 5%/5 mm DD / DTA) are selected. These criteria are evaluated while suppressing the dose of 10%, 20% or 30% from
dose distribution. Results: Point dose evaluations using the ion chamber ranged from -2.6% to 3.7% (mean and standard devia-
tion of 0.46 ± 1.7). Significant differences are observed between the films and 2D-array for all criteria except the 3%/5 mm cri-
teria (96.89 ± 2.2% vs. 94.81 ± 4.2% (p < 0.01)). Conclusion: Differences may exceed about 3% when the ionization chamber is
present in steep dose gradient regions. The present results suggest the gamma criteria of 3%/5 mm as the most suitable criteria
for IMRT quality assurance. This gamma criterion of 3%/5 mm favorably exceeds 95% in case of maximum dose while sup-
pressing the dose of 20%.The use of 2D-array can reduce the IMRT QA workload.
Keywords:Quality Assurance; Intensity Modulation; Ionization Chamber; 2D-Array; GafChromic Films
Introduction
The standard quality assurance (QA) for IMRT before the
patient treatment is to use an ionization chamber for abso-
lute dose measurements and 2-dimensional (2D)-array or
films for relative dose evaluation.1, 2 During the introduction
of intensity-modulated beams applied for IMRT, the physics
community started to perform more extensive verification in
2D (planes) and even in 3D (volumes). Burman et al 3 intro-
duced a concept for IMRT verification. Kron et al 4 per-
formed a check of absolute dose calibration in a slab phan-
tom. This study found that the dose delivered to the ICRU
reference point was correct in all centers. They also found
that the absolute dose calibration and the mean dose in the
target volume were ± 5% for all participating centers. Dong
et al 5 completed a dosimetric verification of 200 cases of
head and neck using ionization chamber for patient-specific
quality assurance. Most treatments were delivered using the
step-and-shoot multileaf collimator with a 6-MV photon
beam. The measured difference was greater than 3.5% for 14
cases. Low and Dempsey 6 typically used 5% and 2-3 mm as
tolerance values of the γ-distribution during their clinical
evaluation. In a more recent study Childress et al 7 analyzed
about 850 films resulting from IMRT plan verification. Their
results showed no dependence on energy, accelerator or
treatment site, but varied for the different QA phantoms and
treatment planning systems applied in their study. Their
preferred gamma index tolerance criteria were 5% and 3
mm. Saminathan et al 8 investigated the use of 2D-array
compared to films in the verification of IMRT. Their meas-
urements showed that the 2D-array could be used to quanti-
fying absolute dose and could be also used for routine quality
assurance checks like flatness, symmetry, field width, and
penumbra of the linear accelerator beam.
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IMRT is an optimal technical approach for the treatment of
head and neck tumors. This is because of the presence of
anatomically critical structures close to the targeted cancer
tissue.9, 10, 11 This complex technique requires a highly effi-
cient treatment-verification process.4 The IMRT delivery
quality assurance mostly consists of delivering the IMRT
plan to a phantom and then comparing the 2D dose distribu-
tion calculated by the treatment planning system (TPS) with
the dose measured using 2D-array or films.1, 2, 12, 13, 14, 18
A “reasonable” choice of a specific combination of gamma
evaluation and acceptance criteria should be based on the
accuracy of the applied measurement procedure, its work-
load, and the ability to detect problem areas in the intended
dose distribution. Combinations of gamma evaluation and
acceptance criteria depend on many factors including the
dosimetric equipment, calculation and measurement grid,
and the data analysis software. It is therefore virtually im-
possible to provide general recommendations applicable for
all situations.13 For these reasons, the goal of this work is
studying the compatibility of IMRT dose calculations for
head and neck tumors in TPS with dose measurement in
Linac at the National Cancer Institute, Cairo, Egypt. Several
tests are performed using ionization chamber, 2D array ioni-
zation chambers and films. Ionization chamber is used for
point dose measurements. 2D array ionization chambers and
films are used to display 2D graphics of dose measurements.
This is to establish a protocol to present a complete QA pro-
cess, evaluate the usefulness of the investigated methods and
suggest the use of faster and more efficient dosimetric tools
for the dose verification in IMRT technique in our institute.
Methods and Materials
QA Tools
The dose measurements are done in rectangular parallel slabs
of water equivalent phantom. The phantom dimensions are
30 × 30 × 25 cm3. Three different tools are used in this study:
1. Ionization Chamber: 0.6 cm3 farmer type
ion-chamber and unidose electrometer (PTW,
Freiburg, Germany) are used for point dose meas-
urements.12, 13, 14, 15 A sandwich setup of water
equivalent PTW RW3 plates with a stack of 15 cm
below and 10 cm above the ionization chamber are
used. The phantom arrangement is scanned in CT
with slice thickness of 0.5 cm. The scanned phan-
tom is imported via DICOM to XIO treatment
planning system.
2. 2D-array: PTW 2D-array 729 consisting of a plan
matrix of 27 × 27 air–filled ionization chambers is
used (PTW, Freiburg, Germany). The detector
spacing (center to center) is 1 cm. The dimensions
of each detector are 0.5 × 0.5 × 0.5 cm3.
3. GafChromic films: EBT2 GafChromic films, each of
dimensions 8 × 10 inches, are used (ISP-USA). The
irradiated films are scanned with Vidar VXR-16
Dosimetry PRO scanner. MEPHYSTO mc2 soft-
ware (PTW, Freiburg, Germany) is used for film
analysis. Films are stored in light-tight envelopes
under constant atmospheric conditions. The same
time difference is maintained between the film ir-
radiation and scanning. Edges of the films are not
included in the region of interest to avoid artifacts.
2D-array and films are used for dose verification for treat-
ment planning system.12, 13 The same setup of water equiva-
lent PTW RW3 plates used for point dose measurements is
used for 2D-array and film measurements. The phantom is
irradiated using the same monitor units and same beam setup
as the patient treatment setup with Elekta Precise linear
accelerator (step-and-shoot IMRT delivery). 2D-array and
films display 2D graphics and transfer the acquired data to
the Verisoft software. Doses are calculated in cGy for 30
patients by inverse planning optimization using CMS XIO
treatment planning system version (4.40). Seven beams are
calculated for every plan. The number of segments may ex-
ceed about 120 segments for a head and neck plan. All of the
measurements are performed on step and shoot Elekta Pre-
cise® linear accelerator.
Verisoft software
The Verisoft software assists physicists in comparing dose
distributions in IMRT verification phantom with dose dis-
tributions computed by radiotherapy treatment planning
system. Matrices of measured and calculated points of an
IMRT beam are compared by subtracting the matrices and
visualizing the results. The software supports the gamma
evaluation method, it helps in locating hot and cold spots
and determines maximum and average deviation between a
calculated and measured plan.
In this study, the Verisoft verification software is used to
compare gamma distribution for calculated dose (cGy) using
TPS and measured dose using films and 2D-array. This is to
find out what percent of pixels passing certain criteria imi-
tate a good quality plan. Two tests are performed for the
comparison between measured dose from Linac and calcu-
lated dose from treatment planning system. The first one
included using four different gamma criteria for local dose.
These criteria are 3%/3 mm, 3%/5 mm, 4%/4 mm and 5%
dose difference (DD)/5 mm distance to agreement (DTA). It
is performed by the suppression of the dose below either of
10%, 20% or 30% from the maximum of the reference ma-
trix. The second test included using the same four gamma
criteria but, in this case, for maximum dose. A comparison
between local and maximum dose for every gamma criteria is
then performed.
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Results & Discussion
Point dose measurements:
The differences between the measured doses by ion chamber
and that calculated for 30 patients (210 fields) using XIO TPS
are expected to range from -2.6 % to 3.7 % for whole plan
(mean and standard deviation equal 0.46 ± 1.7) for head and
neck tumors. In the home protocol one would expect the
ionization chamber measurement to be within 3% of calcu-
lated dose. If the result gives a variation higher than 5% the
QA procedure is repeated. If the variations are between 3%
and 5%, the films or 2D-array can be used for evaluation.
The present results show that 96% of ion chamber measure-
ments vary less than 5% from calculated dose and about 75%
of ion chamber measurements vary less than 3 % from cal-
culated dose (Figure1). Dong et al. 5 reported that the mean
difference between measured and calculated doses was
greater than 3.5 %. Chung et al. 16 stated that the average
difference between measured and computed dose at isocen-
ter for a gantry angle 0° for Head and Neck tumors was -0.55
± 1.51.This corresponded to a range of variation of -4.1% to
+3.9%. Fenoglietto et al. 17 reported a value of 1.33 ± 3.22%
for the difference between measured and calculated dose for
head and neck tumors. Syam Kumar et al. 15 reported also
that a 0.6 cm3 ionization chamber gave 2.23% of the meas-
ured isocenter absolute dose which was comparable to the
calculated plan. In the present results the differences may
reach a maximum of 9% for an individual field. It has been
cited that this difference might reach a maximum of 10%. 13
This large error most probably emerges from the variation in
intensities of modulated beam resulting from the positioning
of the ion chamber in the penumbra region of intensity map
of the field. This may occur because of the size of farmer
type ionization chamber or due to the charged particles
equilibrium around the ion chamber (Figure 2). The same
observation is reported by several authors.15, 18, 19, 20
FIG. 1: Examples of relative difference in dose values between measured dose using 0.6 cm3 ionization chamber and calculated dose using XiO
TPS.
FIG. 2: Comparison between two fields having different intensities for head and neck IMRT cases: A large variation in intensity in the position
of ion chamber can be seen.
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Dose measurements using 2D-array
Four different gamma criteria (dose difference(DD) /distance
to agreement (DTA)) for 30 patients of Head and Neck tu-
mors are compared to decide which criteria is to be used :
3%/3 mm, 3%/5 mm, 4% /4 mm and 5% /5 mm DD/DTA.
Each of these criteria has been suggested elsewhere.2, 7, 21, 22
The choice of the criteria is made so that as much infor-
mation as possible can be obtained and observed. The dose
differences between measured dose (in Linac) and calculated
dose (in TPS) are evaluated while suppressing the dose of
10%, 20% or 30% from dose distribution. A comparison be-
tween the results obtained for all gamma criteria is given
below:
I. Local dose: The comparison between four different
gamma criteria while suppressing the doses below
10%, 20% or 30% for 30 patients of head and neck
tumors is performed. The criteria of 3% / 3 mm
shows gamma passed % < 90%. On the other hand,
the criteria of 5% /5 mm shows gamma passed %
greater than 95% for all suppression doses (10%,
20%, and 30%). Figure 3 shows the gamma criteria
of local dose excluding the lowest 20% of the dose
distribution.
II. Maximum dose: the gamma passed % dropped be-
low 90% at 3% DD, 3 mm DTA, nevertheless the
average data for each criterion has gamma passed %
values exceeding 90%. Day et al. 22 used the gamma
criteria of 4% DD and 4 mm DTA with the lowest
10% of the dose distribution excluded from all
gamma and DTA analyses for head and neck cases
using 2D-array for the quality assurance (QA) of
IMRT. Their result was 99.7% for the average
gamma pass rate. While Zhang et al. 23 found that
the points passed ratio was more than 90% for
13%/3 mm gamma criteria. The authors did not
specify whether their published results were calcu-
lated for maximum dose or local dose. Figure 4
shows the gamma criteria of maximum dose ex-
cluding the lowest 20% of the dose distribution.
FIG. 3: The gamma criteria of local dose excluding the lowest 20% of the dose distribution using 2D array.
FIG. 4: The gamma criteria of maximum dose excluding the lowest 20% of the dose distribution using 2D array.
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A comparison between local and maximum doses for different gamma criteria:
I. When using gamma criteria of 3% DD 3 mm DTA and suppressing dose below 10%, the average and standard devia-
tion for local dose of gamma index are 81.70 ± 6.28 while those for maximum dose of gamma index are 92.48 ± 4.60. In
case of suppressing the dose below 20% the average and standard deviation for local dose are 85.67 ± 4.74 and for
maximum dose are 93.42 ± 3.64. By increasing the value of suppressing dose below 30% the obtained data of average
and standard deviation for local dose are 86.40 ± 5.51 and for maximum dose are 93.03 ± 3.60. From the above men-
tioned results, it is clear that the maximum dose data always show better results compared to local dose for all gamma
values. This large reported difference between the gamma values obtained for maximum dose compared to local dose
necessitates that different authors clarify whether their published results are calculated for maximum dose or local
dose.
II. The calculations of average and standard deviation values for the other criteria (3%/5 mm, 4%/4 mm and 5% /5 mm)
are listed in Table 1. All show greater gamma passed % values for maximum dose compared to local dose.




local Dose Maximum dose
Avg. Stdv Avg. stdv
10% 81.96 6.28 92.48 4.60
20% 85.67 4.74 93.42 3.64
30% 86.40 5.51 93.03 3.60
3%/5 mm
local Dose Maximum dose
Avg. Stdv Avg. Stdv
10% 89.81 4.11 96.72 2.78
20% 91.32 3.67 96.89 2.20
30% 91.78 3.69 96.65 2.32
4%/4 mm
local Dose Maximum dose
Avg. Stdv Avg. Stdv
10% 90.91 4.41 98.17 2.65
20% 93.82 3.05 98.53 1.22
30% 94.10 3.69 98.37 1.32
5%/5 mm
local Dose Maximum dose
Avg. Stdv Avg. Stdv
10% 95.7 2.65 99.46 1.32
20% 97.38 1.57 99.71 0.33
30% 97.66 1.90 99.65 0.38
FIG. 5: The gamma criteria of local dose excluding the lowest 20% of the dose distribution using film.
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FIG. 6: The gamma criteria of maximum dose excluding the lowest 20% of the dose distribution using film.
Dose measurements using Gafchromic EBT2 Films
The same gamma criteria used in 2D-array measurements are
applied for 15 head and neck cancer patients using Gaf-
chromic EBT2 Films in order to compare efficiency of the
different tools (2D-array vs. Gafchromic EBT2 Films). The
obtained results are presented below:
I. Local dose: Similar to 2D-array, the data shows the
highest gamma passed % values (gamma passed %
> 90%) for the 5% DD and 5 mm DTA gamma
criteria while suppressing the dose below 30% for
all gamma criteria. Also the criteria of 3%/3 mm
yield gamma values below 90% as in the case of
2D-array. The gamma criteria of local dose ex-
cluding the lowest 20% of the dose distribution
using Film are shown in Figure 5.
II. Maximum dose: The acceptance limits for γ calcu-
lation are obtained for all gamma criteria. Unlike
2D array, the criteria of 3 % DD and 3 mm DTA
yield values of gamma passed % less than 90%
when suppressing the dose below 10 % only. All
gamma criteria show highest values when sup-
pressing the dose below 30%. Anjum et al. 2 com-
pared between planned dose and irradiated dose
distribution using GafChromic films. The gamma
criteria of 3% dose difference (DD) and 3 mm dis-
tance to agreement (DTA) used for head and neck
tumors in 96.3% of cases gave a gamma passed
percent ≥ 75%. The gamma criteria of maximum
dose excluding the lowest 20% of the dose distri-
bution using Film are shown in Figure 6.
The calculation of average and standard deviation values for
all criteria (3%/3 mm, 3%/5 mm, 4%/4 mm and 5%/5 mm)
are listed in Table 2 all show greater gamma passed % values
for maximum dose compared to local dose.
The results obtained with 2D-array are compared with nu-
merous fluence distributions obtained with Gafchromic films
for all criteria. Only minor differences in the value of gamma
passed % are found. The data indicate a better performance
for 2D-array compared to film. The results are within 0.4%
to 3.3% for local dose and 1.6% to 4.3% for maximum dose.
This is an expected result due to the possible errors resulting
from scanning, temperature, and the dose to optical density
calibration of the film. Ahluwalia and Saini 24 preferred the
2D-array than film and sates that the differences between
them were within 3 to 5%. Létourneau et al. 25 also preferred
the 2D-array than film because the use of 2D-array could
reduce the IMRT QA workload. Saminathan et al. 8 investi-
gated the using of 2D-array in verification of IMRT compar-
ing the data with films. The measurements and evaluation
provided that 2D-array could be used for quantifying abso-
lute dose and could also be used for routine quality assurance
checks like flatness, symmetry, field width, and penumbra of
the linear accelerator beam.
Comparison between film and 2D-array
Local dose
Statistical comparison between film and 2D-array for all
criteria values while suppressing the 10%, 20% and 30%
doses are carried out using Duncan multiple range test at p <
0.01.Significant differences are observed between the films
and 2D-array only for 3%/3 mm criteria (for 10% dose sup-
pression), 4% /4 mm and 5%/5 mm criteria (for 10% and
20% dose suppression).
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local Dose Maximum dose
Avg. Stdv Avg. stdv
10 % 80.19 4.73 88.45 4.04
20 % 83.27 4.69 90.17 3.86
30 % 84.51 6.07 90.57 4.98
3%/5 mm
local Dose Maximum dose
Avg. Stdv Avg. Stdv
10 % 88.74 3.70 93.88 3.56
20 % 90.92 4.40 94.81 4.23
30 % 91.63 5.05 94.98 4.66
4%/4 mm
local Dose Maximum dose
Avg. Stdv Avg. Stdv
10 % 88.66 4.24 94.29 3.28
20 % 90.69 3.73 94.98 3.74
30 % 91.51 4.32 95.13 4.19
5%/5 mm
local Dose Maximum dose
Avg. Stdv Avg. Stdv
10 % 92.54 3.73 97.23 1.79
20 % 94.72 3.14 97.83 1.97
30 % 95.33 3.47 98.03 2.21
Maximum dose
Statistical comparison between film and 2D-array for all
criteria values while suppressing the 10%, 20%, and 30%
doses are carried out using Duncan multiple range test at p <
0.01.Significant differences are observed between the films
and 2D-array for all criteria except the 3%/5 mm criteria.
Conclusion
It is clear that the maximum dose data always show better
results compared to local dose for all gamma values which
are performed by films and 2D-array. The films and
2D-array for local dose show best values for 5% DD and 5
mm DTA for gamma passed % > 90%. Also the best values
are obtained when suppressing the dose below 30% for all
gamma criteria. The criteria of 3%/3 mm show gamma values
below 90%. For maximum dose when using the film, the
criteria of 3% DD and 3 mm DTA give values of gamma
passed % less than 90% when suppressing the dose below
10% only. All gamma criteria produced the highest values
when suppressing the dose below 30%. Unlike film when
using 2D-array, the average data for each criterion has gam-
ma passed % exceeding 90%.This large reported difference
between the gamma values obtained for maximum dose
compared to local dose necessitates that different authors
clarify whether their published results are calculated for
maximum dose gamma index or local dose gamma index.
The data indicate also a better performance for 2D-array
compared to film. The results obtained with 2D-array are
compared with numerous fluence distributions obtained
with Gafchromic films for all criteria. Only minor differ-
ences in the value of gamma passed % are reported. These
differences are within 0.4% to 3.3% for local dose and 1.6 %
to 4.3 % for maximum dose. This is an expected result due to
the possible errors resulting from scanning, temperature and
the dose to optical density calibration of the film. The use of
2D-array can reduce the IMRT QA workload. Based on the
results of this work, the criteria of 3% DD and 5 mm DTA
while suppressing the dose below 20% are recommended.
These criteria are also reported by Anjum et al. 2. Under
this criterion the percent of pixels passing gamma is > 95% in
case of maximum dose.
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